Drugs / CMAB008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03478111 | Mar 2018 → Jun 2019 | rheumatoid arthritis | Shanghai Biomabs Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMAB008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03478111 ↗ |
| Action | Inhibit | “anti-TNF-α monoclonal antibody” NCT03478111 ↗ |
| Modality | Monoclonal antibody | “CMAB008 (recombinant chimeric anti-TNF-α monoclonal antibody injection)” NCT03478111 ↗ |
| Route | Intravenous | “receive intravenously CMAB008 3 mg/kg or innovator infliximab 3 mg/kg at weeks 0, 2, 6, 14, 22 and 30” PMID 36964872 ↗ Mar 2023 |
| Target | TNF | “anti-TNF-α monoclonal antibody” NCT03478111 ↗ |